Publication

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study

Risselada, A. J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A. F., Arends, J. & Mulder, H., Feb-2012, In : Pharmacogenomics journal. 12, 1, p. 62-67 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Risselada, A. J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A. F., ... Mulder, H. (2012). Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics journal, 12(1), 62-67. https://doi.org/10.1038/tpj.2010.66

Author

Risselada, A. J. ; Vehof, J. ; Bruggeman, R. ; Wilffert, B. ; Cohen, D. ; Al Hadithy, A. F. ; Arends, J. ; Mulder, H. / Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics : a replication study. In: Pharmacogenomics journal. 2012 ; Vol. 12, No. 1. pp. 62-67.

Harvard

Risselada, AJ, Vehof, J, Bruggeman, R, Wilffert, B, Cohen, D, Al Hadithy, AF, Arends, J & Mulder, H 2012, 'Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study', Pharmacogenomics journal, vol. 12, no. 1, pp. 62-67. https://doi.org/10.1038/tpj.2010.66

Standard

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics : a replication study. / Risselada, A. J.; Vehof, J.; Bruggeman, R.; Wilffert, B.; Cohen, D.; Al Hadithy, A. F.; Arends, J.; Mulder, H.

In: Pharmacogenomics journal, Vol. 12, No. 1, 02.2012, p. 62-67.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics journal. 2012 Feb;12(1):62-67. https://doi.org/10.1038/tpj.2010.66


BibTeX

@article{807997caab4642e990244bea2702726b,
title = "Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study",
abstract = "In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C > G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95{\%} confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome. The Pharmacogenomics Journal (2012) 12, 62-67; doi:10.1038/tpj.2010.66; published online 3 August 2010",
keywords = "HTR2C, antipsychotics, metabolic syndrome, schizophrenia, INDUCED WEIGHT-GAIN, 5-HT2C RECEPTOR, DRUG-TREATMENT, SCHIZOPHRENIC-PATIENTS, C/T POLYMORPHISM, OLANZAPINE, PREVALENCE",
author = "Risselada, {A. J.} and J. Vehof and R. Bruggeman and B. Wilffert and D. Cohen and {Al Hadithy}, {A. F.} and J. Arends and H. Mulder",
year = "2012",
month = "2",
doi = "10.1038/tpj.2010.66",
language = "English",
volume = "12",
pages = "62--67",
journal = "Pharmacogenomics journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics

T2 - a replication study

AU - Risselada, A. J.

AU - Vehof, J.

AU - Bruggeman, R.

AU - Wilffert, B.

AU - Cohen, D.

AU - Al Hadithy, A. F.

AU - Arends, J.

AU - Mulder, H.

PY - 2012/2

Y1 - 2012/2

N2 - In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C > G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome. The Pharmacogenomics Journal (2012) 12, 62-67; doi:10.1038/tpj.2010.66; published online 3 August 2010

AB - In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C > G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome. The Pharmacogenomics Journal (2012) 12, 62-67; doi:10.1038/tpj.2010.66; published online 3 August 2010

KW - HTR2C

KW - antipsychotics

KW - metabolic syndrome

KW - schizophrenia

KW - INDUCED WEIGHT-GAIN

KW - 5-HT2C RECEPTOR

KW - DRUG-TREATMENT

KW - SCHIZOPHRENIC-PATIENTS

KW - C/T POLYMORPHISM

KW - OLANZAPINE

KW - PREVALENCE

U2 - 10.1038/tpj.2010.66

DO - 10.1038/tpj.2010.66

M3 - Article

VL - 12

SP - 62

EP - 67

JO - Pharmacogenomics journal

JF - Pharmacogenomics journal

SN - 1470-269X

IS - 1

ER -

ID: 5492995